Exciting Aspects in AML Therapies in 2021 and Beyond
In this segment, “Exciting Aspects in AML Therapies in 2021 and Beyond” Naval Daver, MD, and Eunice Wang, MD, highlight recent progress and future directions in AML.
The identification of AML-specific immune pathways may potentially lead to progress with immunotherapy and cellular therapy in a disease where immune-based approaches have historically been unsuccessful. Further improving on the efficacy of single-agent targeted therapy, doublet and triplet therapies have yielded impressive results. Emerging data on menin inhibitors and the role of maintenance therapy is also discussed.